These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 23487168)

  • 61. Azilsartan medoxomil in the treatment of hypertension: the definitive angiotensin receptor blocker?
    Barrios V; Escobar C
    Expert Opin Pharmacother; 2013 Nov; 14(16):2249-61. PubMed ID: 24070321
    [TBL] [Abstract][Full Text] [Related]  

  • 62. The velocity of antihypertensive effects of seven angiotensin II receptor blockers determined by home blood pressure measurements.
    Satoh M; Haga T; Hosaka M; Obara T; Metoki H; Murakami T; Kikuya M; Inoue R; Asayama K; Mano N; Ohkubo T; Imai Y
    J Hypertens; 2016 Jun; 34(6):1218-23. PubMed ID: 27027425
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Comparative effectiveness of angiotensin-receptor blockers for preventing macrovascular disease in patients with diabetes: a population-based cohort study.
    Antoniou T; Camacho X; Yao Z; Gomes T; Juurlink DN; Mamdani MM
    CMAJ; 2013 Sep; 185(12):1035-41. PubMed ID: 23836857
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Azilsartan as a Potent Antihypertensive Drug with Possible Pleiotropic Cardiometabolic Effects: A Review Study.
    Georgiopoulos G; Katsi V; Oikonomou D; Vamvakou G; Koutli E; Laina A; Tsioufis C; Nihoyannopoulos P; Tousoulis D
    Front Pharmacol; 2016; 7():235. PubMed ID: 27536242
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Effects of combining azilsartan medoxomil with amlodipine in patients with stage 2 hypertension.
    Weber MA; White WB; Sica D; Bakris GL; Cao C; Roberts A; Kupfer S
    Blood Press Monit; 2014 Apr; 19(2):90-7. PubMed ID: 24445723
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Effects of azilsartan medoxomil compared with olmesartan and valsartan on ambulatory and clinic blood pressure in patients with type 2 diabetes and prediabetes.
    White WB; Cuadra RH; Lloyd E; Bakris GL; Kupfer S
    J Hypertens; 2016 Apr; 34(4):788-97. PubMed ID: 26766564
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Effects of azilsartan compared to other angiotensin receptor blockers on left ventricular hypertrophy and the sympathetic nervous system in hemodialysis patients.
    Kusuyama T; Ogata H; Takeshita H; Kohno H; Shimodozono S; Iida H; Tsukazaki T
    Ther Apher Dial; 2014 Oct; 18(5):398-403. PubMed ID: 24571483
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Depressor and Anti-Inflammatory Effects of Angiotensin II Receptor Blockers in Metabolic and/or Hypertensive Patients With Coronary Artery Disease: A Randomized, Prospective Study (DIAMOND Study).
    Adachi S; Miura S; Shiga Y; Arimura T; Kuwano T; Kitajima K; Ike A; Sugihara M; Iwata A; Nishikawa H; Morito N; Saku K
    J Clin Med Res; 2016 Oct; 8(10):743-8. PubMed ID: 27635180
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Possible benefits of azilsartan compared with other angiotensin II type 1 receptor blockers.
    Miura S; Saku K
    Hypertens Res; 2014 Sep; 37(9):799-800. PubMed ID: 25007763
    [No Abstract]   [Full Text] [Related]  

  • 70. Patients With Newly Diagnosed Hypertension Treated With the Renin Angiotensin Receptor Blocker Azilsartan Medoxomil vs Angiotensin-Converting Enzyme Inhibitors: The Prospective EARLY Registry.
    Schmieder RE; Potthoff SA; Bramlage P; Baumgart P; Mahfoud F; Buhck H; Ouarrak T; Ehmen M; Senges J; Gitt AK;
    J Clin Hypertens (Greenwich); 2015 Dec; 17(12):947-53. PubMed ID: 26105590
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Reassessment of the unique mode of binding between angiotensin II type 1 receptor and their blockers.
    Miura S; Nakao N; Hanzawa H; Matsuo Y; Saku K; Karnik SS
    PLoS One; 2013; 8(11):e79914. PubMed ID: 24260317
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Effect of azilsartan versus candesartan on morning blood pressure surges in Japanese patients with essential hypertension.
    Rakugi H; Kario K; Enya K; Sugiura K; Ikeda Y
    Blood Press Monit; 2014 Jun; 19(3):164-9. PubMed ID: 24710336
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Single-center evaluation of the single-dose pharmacokinetics of the angiotensin II receptor antagonist azilsartan medoxomil in renal impairment.
    Preston RA; Karim A; Dudkowski C; Zhao Z; Garg D; Lenz O; Sica DA
    Clin Pharmacokinet; 2013 May; 52(5):347-58. PubMed ID: 23575872
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Safety and tolerability of azilsartan medoxomil in subjects with essential hypertension: a one-year, phase 3, open-label study.
    Handley A; Lloyd E; Roberts A; Barger B
    Clin Exp Hypertens; 2016; 38(2):180-8. PubMed ID: 26817604
    [TBL] [Abstract][Full Text] [Related]  

  • 75. [Azilsartan--new representative of the class of angiotensin receptor blockers II].
    Ostroumova OD
    Kardiologiia; 2014; 54(9):65-71. PubMed ID: 25702405
    [TBL] [Abstract][Full Text] [Related]  

  • 76. EARLY Treatment with azilsartan compared to ACE-inhibitors in anti-hypertensive therapy--rationale and design of the EARLY hypertension registry.
    Gitt AK; Baumgart P; Bramlage P; Mahfoud F; Potthoff SA; Senges J; Schneider S; Buhck H; Schmieder RE;
    BMC Cardiovasc Disord; 2013 Jul; 13():46. PubMed ID: 23819631
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Efficacy and safety of 10-mg azilsartan compared with 8-mg candesartan cilexetil in Japanese patients with hypertension: a randomized crossover non-inferiority trial.
    Takahara M; Shiraiwa T; Shindo M; Arai A; Kusuda Y; Katakami N; Kaneto H; Matsuoka TA; Shimomura I
    Hypertens Res; 2014 Sep; 37(9):852-7. PubMed ID: 24739538
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Rationale, study design, and implementation of the ACS1 study: effect of azilsartan on circadian and sleep blood pressure as compared with amlodipine.
    Kario K; Hoshide S
    Blood Press Monit; 2014 Jun; 19(3):123-8. PubMed ID: 24637789
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Difference in the effects of switching from candesartan to olmesartan or telmisartan to olmesartan in hypertensive patients with type 2 diabetes: the COTO study.
    Daikuhara H; Fukunaga K; Ohshima T
    Drug Des Devel Ther; 2014; 8():219-26. PubMed ID: 24600204
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Comparative effect of angiotensin II type I receptor blockers on serum uric acid in hypertensive patients with type 2 diabetes mellitus: a retrospective observational study.
    Nishida Y; Takahashi Y; Susa N; Kanou N; Nakayama T; Asai S
    Cardiovasc Diabetol; 2013 Nov; 12():159. PubMed ID: 24180232
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.